M. McIlraith

1.5k total citations · 1 hit paper
18 papers, 670 citations indexed

About

M. McIlraith is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, M. McIlraith has authored 18 papers receiving a total of 670 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Rheumatology, 9 papers in Immunology and 4 papers in Hematology. Recurrent topics in M. McIlraith's work include Rheumatoid Arthritis Research and Therapies (7 papers), Spondyloarthritis Studies and Treatments (5 papers) and T-cell and B-cell Immunology (5 papers). M. McIlraith is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (7 papers), Spondyloarthritis Studies and Treatments (5 papers) and T-cell and B-cell Immunology (5 papers). M. McIlraith collaborates with scholars based in United States, Germany and United Kingdom. M. McIlraith's co-authors include Remo Panaccione, Ana P. Lacerda, Kenneth B. Gordon, Gerd R Burmester, Peter E. Lipsky, Ranjeny Thomas, Laurie S. Davis, Amrie C. Grammer, J F Attrep and Toshiyuki Miyashita and has published in prestigious journals such as The Journal of Immunology, Gastroenterology and Annals of the New York Academy of Sciences.

In The Last Decade

M. McIlraith

18 papers receiving 653 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

2012 433 citations Gerd R Burmester, Remo Panaccione et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. McIlraith United States	7	362	225	130	101	94	18	670
Animesh Singh United Kingdom	4	800 2.2×	297 1.3×	111 0.9×	70 0.7×	103 1.1×	7	1.1k
Ziyan Wu China	14	170 0.5×	278 1.2×	97 0.7×	115 1.1×	95 1.0×	68	638
Nobuaki Hatta Japan	6	368 1.0×	261 1.2×	118 0.9×	136 1.3×	135 1.4×	7	743
Makio Kusaoi Japan	15	441 1.2×	338 1.5×	51 0.4×	93 0.9×	55 0.6×	39	716
Paul D. Doodes United States	7	492 1.4×	168 0.7×	52 0.4×	40 0.4×	34 0.4×	7	652
Daisuke Kashiwakuma Japan	13	499 1.4×	215 1.0×	47 0.4×	98 1.0×	40 0.4×	17	901
W E Ollier United Kingdom	15	380 1.0×	562 2.5×	66 0.5×	296 2.9×	84 0.9×	20	897
Marie‐Louise Frémond France	17	432 1.2×	212 0.9×	96 0.7×	131 1.3×	80 0.9×	38	711
M. Hirakata Japan	16	235 0.6×	318 1.4×	102 0.8×	337 3.3×	44 0.5×	42	888
Aurélie Ambrosi Sweden	13	471 1.3×	339 1.5×	29 0.2×	85 0.8×	100 1.1×	18	862

Countries citing papers authored by M. McIlraith

Since Specialization

Citations

This map shows the geographic impact of M. McIlraith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. McIlraith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. McIlraith more than expected).

Fields of papers citing papers by M. McIlraith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. McIlraith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. McIlraith. The network helps show where M. McIlraith may publish in the future.

Co-authorship network of co-authors of M. McIlraith

This figure shows the co-authorship network connecting the top 25 collaborators of M. McIlraith. A scholar is included among the top collaborators of M. McIlraith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. McIlraith. M. McIlraith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Mease, Philip J., M. Elaine Husni, Evan Siegel, et al.. (2025). What Matters in Psoriatic Arthritis: A Comparison of Patient and Clinician Perspectives. ACR Open Rheumatology. 7(1). e11781–e11781. 2 indexed citations

Blanco, Francisco J., Jeffrey Crowley, M. McIlraith, et al.. (2017). FRI0487 Apremilast is associated with long-term (4-YEAR) DAS-28 (CRP) remission and improvements in skin disease: results from a phase iii study in dmard/biologic-experienced patients with active psoriatic arthritis. Annals of the Rheumatic Diseases. 76. 672–672. 4 indexed citations

Gladman, DD, Arthur Kavanaugh, J. Wollenhaupt, et al.. (2017). SAT0448 Apremilast treatment and long-term (up to 156 weeks) improvements in dactylitis and enthesitis in patients with psoriatic arthritis: analysis of a large database of the phase iii clinical development program. Annals of the Rheumatic Diseases. 76. 942–942. 1 indexed citations

Marzo‐Ortega, Helena, Airi Põder, Filip Van den Bosch, et al.. (2017). FRI0512 Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (156-week) improvements in basdai in psoriatic arthritis patients: pooled results from 3 phase iii, randomized, controlled trials. Annals of the Rheumatic Diseases. 76. 683–684. 2 indexed citations

Wollenhaupt, J., Stephen Hall, Filip Van den Bosch, et al.. (2017). FRI0513 Long-term (156 weeks) improvements in physical function of dmard-naÏve and dmard/biologic-experienced psoriatic arthritis patients treated with apremilast: data from a large database of 4 phase iii clinical trials. Annals of the Rheumatic Diseases. 76. 684–685. 1 indexed citations

Gladman, Dafna D., Arthur Kavanaugh, Adewale Adebajo, et al.. (2016). O03 Apremilast, an Oral Phosphodiesterase-4 Inhibitor, is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III Randomized Controlled Trials. Lara D. Veeken. 1 indexed citations

Mease, Philip J., Helena Marzo‐Ortega, Airi Põder, et al.. (2016). THU0420 Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in BASDAI in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase III, Randomized, Controlled Trials. Annals of the Rheumatic Diseases. 75. 341–341. 1 indexed citations

Gladman, Dafna D., Arthur Kavanaugh, Ade Adebajo, et al.. (2015). OP0169 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase 3, Randomized, Controlled Trials. Annals of the Rheumatic Diseases. 74. 133–134. 7 indexed citations

Burmester, Gerd R, Remo Panaccione, Kenneth B. Gordon, M. McIlraith, & Ana P. Lacerda. (2012). Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Annals of the Rheumatic Diseases. 72(4). 517–524. 433 indexed citations breakdown →

10.

Burmester, Gerd‐Rüdiger, Remo Panaccione, Kenneth B. Gordon, M. McIlraith, & Ana P. Lacerda. (2012). SAT0130 Long-term safety of adalimumab in patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, and crohn's disease. Annals of the Rheumatic Diseases. 71. 514–515. 12 indexed citations

11.

Breedveld, F. C., Edward Keystone, D. van der Heijde, et al.. (2011). Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial. Data Archiving and Networked Services (DANS). 63(10). 118–119. 5 indexed citations

12.

Hanauer, Stephen B., Michael A. Kamm, Remo Panaccione, et al.. (2008). T1131 Steroid-Free Remission Over 2 Years in Crohn's Patients Receiving Adalimumab: the Open-Label Extension of the CHARM Trial. Gastroenterology. 134(4). A–490. 4 indexed citations

13.

Kamm, MA, Stephen B. Hanauer, Remo Panaccione, et al.. (2008). P043 LONG-TERM STEROID-FREE REMISSION IN CROHN'S PATIENTS RECEIVING ADALIMUMAB: THE CHARM TRIAL. 2(1). 18–18. 1 indexed citations

14.

Foy, Teresa M., M. McIlraith, Sally R. Masters, et al.. (1998). Blockade of Cd40-Cd154 Interferes with Human T cell Engraftment in Scid Mice. Cell Transplantation. 7(1). 25–35. 9 indexed citations

15.

Miyashita, Toshiyuki, M. McIlraith, Amrie C. Grammer, et al.. (1997). Bidirectional regulation of human B cell responses by CD40-CD40 ligand interactions. The Journal of Immunology. 158(10). 4620–4633. 73 indexed citations

16.

Lipsky, Peter E., J F Attrep, Amrie C. Grammer, M. McIlraith, & Yuichi Nishioka. (1997). Analysis of CD40‐CD40 Ligand Interactions in the Regulation of Human B Cell Function^a. Annals of the New York Academy of Sciences. 815(1). 372–380. 34 indexed citations

17.

Davis, Laurie S., M. McIlraith, Leah Adix, et al.. (1994). Assessment of a positive selection technique using an avidin column to isolate human peripheral blood T cell subsets. Journal of Immunological Methods. 175(2). 247–257. 6 indexed citations

18.

Thomas, Ranjeny, M. McIlraith, Laurie S. Davis, & Peter E. Lipsky. (1992). Rheumatoid synovium is enriched in CD45RB^dim mature memory T cells that are potent helpers for B cell differentiation. Arthritis & Rheumatism. 35(12). 1455–1465. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact